EVOVEST GLOBAL EQUITY ETF UNITS CAD

Evotec has joined the NURTuRE-AKI consortium led by Kidney Research UK to establish the world's most comprehensive patient cohort for acute kidney injury research.

Sernova Biotherapeutics announced the resignation of Chairman Ross Haghighat, effective May 24, 2025, with the board accepting his departure and thanking him for his leadership.

Peptone and Evotec have established a strategic partnership to accelerate the development of small molecule therapeutics targeting intrinsically disordered proteins (IDPs) across multiple therapeutic areas, including oncology and immunology.

The Gates Foundation has awarded Evotec a $2.5 million grant to support the development of next-generation tuberculosis treatment regimens, building on their five-year partnership.

Evotec SE announced significant progress in its strategic protein degradation collaboration with Bristol Myers Squibb, triggering performance-based payments totaling $75 million.

Oxford-based SynaptixBio has identified SB H-19642, an antisense oligonucleotide drug candidate, to advance into clinical trials for H-ABC, a rare and currently incurable form of TUBB4A-related leukodystrophy.

• Dr. Aidan Synnott, former Corporate VP at Charles River Laboratories with over 20 years of biomedical research experience, has been appointed CEO of Oncodesign Services to enhance client collaboration and scientific quality. • The appointment marks a significant milestone in Oncodesign's transformation following its acquisition of ZoBio and expansion into molecular radiotherapy and protein sciences. • Synnott will focus on aligning the company's structure with drug discovery priorities, integrating operations across Europe and North America, and creating a unified offering to accelerate client programs.

Sernova Biotherapeutics' Phase 1/2 clinical trial for its Cell Pouch Bio-hybrid Organ has received DSMB approval to enroll the final patient in Cohort B and advance to Cohort C in H2 2025.

• Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases. • This marks Roche's second major molecular glue deal in a month, following a similar $2 billion alliance with Orionis Biosciences, demonstrating the company's strategic push to establish leadership in this emerging therapeutic category. • Monte Rosa will lead discovery and preclinical activities using its QuEEN platform, with Roche taking over late-stage development of candidates that can potentially address the 80% of human proteins currently inaccessible to traditional drug development approaches.

Evotec has achieved a significant milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering a $20 million research payment to advance a promising pre-clinical neurodegeneration program.